rethinkTHC Search
Menu
Study breakdown

A Single Amino Acid Change Eliminated Cannabinoid Effects on Pain-Related Glycine Receptors

Animal StudyPreliminary evidence
The takeaway

Mutating a single amino acid (serine to isoleucine at position 267) in the glycine receptor alpha1 subunit abolished the ability of CBD, ajulemic acid, and HU210 to modulate glycine receptor function.

Read this if you study pain pharmacology or cannabinoid mechanisms beyond CB1/CB2 receptors.

One amino acid change abolished all cannabinoid-glycine receptor interactions

What the researchers found

Loss of inhibitory glycine signaling in the spinal cord plays a key role in chronic pain. Recent research suggested that cannabinoids might relieve pain partly by modulating glycine receptors, independent of cannabinoid receptors.

Researchers tested three non-psychotropic cannabinoids (ajulemic acid, CBD, and HU210) on glycine receptors with a specific mutation: serine to isoleucine at position 267 in the transmembrane domain.

This single amino acid change completely abolished the ability of all three cannabinoids to co-activate or directly activate glycine receptors.

This demonstrated that position 267 in the TM2 domain is crucial for cannabinoid-glycine receptor interactions, providing insight into the molecular basis of cannabinoid pain relief through non-CB1/CB2 mechanisms.

Why it matters

Understanding how cannabinoids relieve pain through non-cannabinoid receptor mechanisms (like glycine receptors) could lead to pain medications that work through the cannabinoid-glycine interaction without producing psychoactive effects.

The numbers in context

One amino acid mutation (S267I) abolished all cannabinoid-glycine receptor interactions. Three cannabinoids tested: ajulemic acid, CBD, HU210. All effects eliminated by the mutation.

How the study worked

In vitro electrophysiology study. Mutated alpha1(S267I) glycine receptors were expressed in HEK293 cells and studied using whole-cell patch clamp technique. Three cannabinoids (ajulemic acid, cannabidiol, HU210) were tested for their ability to modulate glycine receptor currents.

What this study cannot tell us

In vitro study using recombinant receptors in cell lines, not native neurons. The mutation may affect receptor function in ways beyond cannabinoid interactions. Whether this mechanism contributes significantly to pain relief in living organisms was not tested.

How to read the evidence

In vitro electrophysiology study with recombinant receptors. Provides precise molecular data but limited translational relevance.

When this study was published

Published in 2010. The cannabinoid-glycine receptor interaction has continued to be studied as a potential target for non-psychoactive pain treatments.

The bigger picture

Pain relief through glycine receptor modulation represents a fundamentally different mechanism from traditional cannabinoid receptor activation. Drugs designed to exploit this specific interaction could potentially provide pain relief without the psychoactive effects or abuse potential of THC.

Questions still open

  • How important is glycine receptor modulation for the overall analgesic effect of cannabinoids? Could drugs be designed to specifically target the cannabinoid-glycine receptor interaction? Do natural variations in glycine receptor genes affect pain responses to cannabinoids?

Common questions

What are glycine receptors?
Glycine receptors are proteins in the spinal cord that normally inhibit pain signaling. When they are not working properly, chronic pain can develop. Some cannabinoids appear to enhance glycine receptor function, which may contribute to their pain-relieving effects.
Why does this matter for CBD pain relief?
CBD does not strongly bind to cannabinoid receptors (CB1/CB2), so its pain-relieving effects must involve other mechanisms. This study showed that CBD modulates glycine receptors, and identified the exact molecular site responsible, which could help develop targeted pain drugs.

Read the original research

Lack of positive allosteric modulation of mutated alpha(1)S267I glycine receptors by cannabinoids.

Naunyn-Schmiedeberg's archives of pharmacology, 381(5), 477-82

Citation

Foadi, Nilufar; Leuwer, Martin; Demir, Reyhan; Dengler, Reinhard; Buchholz, Vanessa; de la Roche, Jeanne; Karst, Matthias; Haeseler, Gertrud; Ahrens, Jörg. (2010). Lack of positive allosteric modulation of mutated alpha(1)S267I glycine receptors by cannabinoids.. Naunyn-Schmiedeberg's archives of pharmacology, 381(5), 477-82. https://doi.org/10.1007/s00210-010-0506-9

Explore the wider topic